Skip to main
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 50%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings is a leading company in the orthopedic reconstructive implants and surgical equipment market, with a leading share in the United States, Europe, and Japan. The company's recent acquisition of Biomet and focus on large joints and extremities, trauma, and sports medicine products make it well-positioned for future growth. While the first quarter performance may have raised some questions and caused confusion, the company's ongoing strategic initiatives, new product launches, and salesforce optimization efforts provide a positive long-term outlook. However, there are some concerns regarding possible competition, quarterly performance consistency, and the success of new product innovations. Overall, the company's strong fundamentals and ongoing transformation efforts support a positive outlook for growth and improved margins in the years ahead.

Bears say

Zimmer Biomet Holdings is facing multiple challenges that may impede its growth in the future, such as a decline in sales in the US for large joint recon products, labor strikes on the West Coast, and ongoing product rationalizations. The company also has significant international exposure, making it vulnerable to changing market dynamics and potential competition from new market entrants. Furthermore, the company's high level of leverage and focus on recon markets may make it difficult for ZBH to rebound in the event of a volume decline or continued pricing pressure.

ZBH has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 50% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 18 analysts, ZBH has a Hold consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.